Pacific Edge Limited (PEB.AX)
- Previous Close
0.0790 - Open
0.0700 - Bid 0.0700 x --
- Ask 0.1100 x --
- Day's Range
0.0700 - 0.0700 - 52 Week Range
0.0700 - 0.4250 - Volume
2,500 - Avg. Volume
11,676 - Market Cap (intraday)
60.771M - Beta (5Y Monthly) 1.01
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore. The company operates in two segments, Commercial and Research. It offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. The company is also developing Cxbladder Resolve, a product that identifies those patients who are likely to have aggressive or more advanced bladder cancer; Cxbladder Triage, a product that identifies patients with haematuria who have a low probability of bladder cancer; Cxbladder Detect that enables the non-invasive detection of bladder and other urinary tract cancers; and Cxbladder Monitor, which allows urologists to monitor bladder cancer patients for recurrence of the disease. In addition, it is developing products for bladder, gastric, colorectal, endometrial cancers, and melanoma. The company was incorporated in 2001 and is headquartered in Dunedin, New Zealand.
www.pacificedgedx.comRecent News: PEB.AX
Performance Overview: PEB.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PEB.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PEB.AX
Valuation Measures
Market Cap
60.73M
Enterprise Value
5.22M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.16
Price/Book (mrq)
0.91
Enterprise Value/Revenue
0.25
Enterprise Value/EBITDA
-0.15
Financial Highlights
Profitability and Income Statement
Profit Margin
-124.01%
Return on Assets (ttm)
-24.07%
Return on Equity (ttm)
-37.87%
Revenue (ttm)
25.52M
Net Income Avi to Common (ttm)
-31.65M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
62.17M
Total Debt/Equity (mrq)
2.07%
Levered Free Cash Flow (ttm)
-19.71M
Company Insights: PEB.AX
PEB.AX does not have Company Insights